Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of Amimestrocel Injection for steroid-refractory acute graft-versus-host disease
CTR20263893Phase 3Active
- Sponsor
- Bosen Biotech
- Start
- Oct 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of amimestrocel in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Bosen Biotech. Started Oct 2026; status: active.
02
Drugs
amimestrocel
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20263893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263893.